Apr 30, 2020
Switching Patterns Among Relapsing-Remitting Multiple Sclerosis: Genentech's Ocrevus on the Rise, Biogen's Tecfidera Declines, and Teva's Copaxone Remains Strong, According to Spherix Global Insights
Mar 10, 2020
Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's Vumerity Begins to Chip Away at the Company's Own Tecfidera
Dec 10, 2019
Neurologists Anticipate Overall Expansion of the Fumarate Class Following the US Launch of Biogen's Vumerity for Treatment in Multiple Sclerosis, According to Spherix Global Insights
Nov 12, 2019
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY(TM)
Jul 30, 2019
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Jun 26, 2019
With Novartis' Mayzent Firmly Positioned for Transitioning Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Use, EMD Serono's Mavenclad Could Be Most Competitive as an Ideal First Switch Following Efficacy Failure
Apr 10, 2019
Preferential First-Line Use of Biogen's Tecfidera and Continued Uptake of Merck KGaA's Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year
Feb 25, 2019
Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Dec 17, 2018
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Oct 12, 2018
Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, Evobrutinib in RMS
Oct 09, 2018
Uptake of Biogen's Tecfidera and Increased Availability of Merck KGaA's Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva's Copaxone
Jun 06, 2018
Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program